Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
β-Amyloid: Enemy or Remedy?
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients
Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO)
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid.
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.
Progressive Multifocal Leukoencephalopathy: Why Gray and White Matter.
Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?
Insight into the mechanism of laquinimod action.
Masitinib is being investigated in the treatment of amyotrophic lateral sclerosis (ALS)
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study.
Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication.
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.
Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro.
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians.
Receptos to initiate Phase 3 trial of RPC1063 in relapsing multiple sclerosis
Gene Expression & Signaling in the Immune System
Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
Teriflunomide for multiple sclerosis.
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
Estriol Treatment in Multiple Sclerosis: Effect on Cognition
Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis.
ARESTIN®
Pages
« first
‹ previous
…
95
96
97
98
99
100
101
102
103
…
next ›
last »